Skip to main content
SpringerLink
Log in

Lessons for transplantation of cyclosporine experience in the treatment of autoimmune diseases

  • Chapter
Book cover Modern Immunosuppressives

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

  • 100 Accesses

Abstract

The emergence of cyclosporine A (CsA) has opened a new era in the approach of chemically induced immunosuppression. The discovery of its molecular mode of action unraveled a whole yet unknown pathway of receptor-ligand systems controlling cytokine transcription. Multiple in vitro studies have extrapolated to human lymphocytes much of the numerous data obtained in murine models either in vitro or in vivo. Much less direct information is available though on the precise mode of action of the drug in man.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bach JF, Strom TB (eds) (1985) The mode of action of immunosuppressive agents. (Research Monographs in Immunology, vol. 9). Amsterdam: Elsevier

    Google Scholar 

  2. Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, Shupack J, Weinstein G (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Amer Acad Dermatol 39: 464–475

    Article  CAS  Google Scholar 

  3. Dick AD, Azim M, Forrester JV (1997) Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Brit J Ophtalmol 81: 1107–1112

    Article  CAS  Google Scholar 

  4. Yocum DE, Torley H (1995) Cyclosporine in rheumatoid arthritis. Rheum Dis Clin N Amer 21: 835–844

    CAS  Google Scholar 

  5. Stephens RB, Lee ML, Cooper A (1994) Cyclosporin treatment of atopic dermatitis: five case studies and literature review. Australas J Dermatol 35: 55–59

    Article  PubMed  CAS  Google Scholar 

  6. Meyrier A (1997) Treatment of idiopathic nephrotic syndrome with cyclosporine A. J Nephrol 10: 14–24

    PubMed  CAS  Google Scholar 

  7. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A et al (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2: 119–124

    Article  PubMed  CAS  Google Scholar 

  8. Coren ME, Rosenthal M, Bush A (1997) The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 77: 522–523

    Article  PubMed  CAS  Google Scholar 

  9. Palestine AG, Austin H. D, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB (1986) Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314: 1293–1298

    Article  CAS  Google Scholar 

  10. Nicolas JF, Chamchick N, Thivolet J, Wijdenes J, Morel P, Revillard JP (1991) CD4 antibody treatment of severe psoriasis. Lancet 338: 321

    Article  PubMed  CAS  Google Scholar 

  11. Bachelez H, Flageul B, Dubertret L, Fraitag S, Grossman R, Brousse N, Poisson D, Knowles RW, Wacholtz MC, Haverty TP et al (1998) Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun 11: 53–62

    Article  PubMed  CAS  Google Scholar 

  12. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP (1994) Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330: 7–14

    Article  PubMed  CAS  Google Scholar 

  13. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316: 719–724

    Article  PubMed  CAS  Google Scholar 

  14. Feutren G, Querin S, Noel LH, Chatenoud L, Beaurain G, Tron F, Lesavre P, Bach JF (1987) Effects of cyclosporine in severe systemic lupus erythematosus. J Pediat 111: 1063–1068

    Article  PubMed  CAS  Google Scholar 

  15. Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ (1989) Cyclosporin in the treatment of lupus nephritis. Amer J Nephrol 9: 57–60

    Article  Google Scholar 

  16. Takahashi S, Nose M, Sasaki J, Yamamoto T, Kyogoku M (1991) IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J Immunol 147: 515–519

    PubMed  CAS  Google Scholar 

  17. Muller C, Zielinski CC, Kalinowski W, Wolf H, Mannhalter JW, Aschauer Treiber G, Klosch Kasparek D, Gaube S, Eibl MM, Schernthaner G (1989) Effects of cyclosporin A upon humoral and cellular immune parameters in insulin-dependent diabetes mellitus type I: a long-term follow-up study. J Endocrinol 121: 177–183

    Article  PubMed  CAS  Google Scholar 

  18. Boitard C, Feutren G, Castano L, Debray-Sachs M, Assan R, Hors J, Bach JF (1987) Effect of cyclosporin A treatment on the production of antibody in insulin-dependent (type I) diabetic patients. J Clin Invest 80: 1607–1612

    Article  PubMed  CAS  Google Scholar 

  19. Terada N, Or R, Weinberg K, Domenico J, Lucas JJ, Gelfand EW (1992) Transcription of IL-2 and IL-4 genes is not inhibited by cyclosporin A in competent T cells. J Biol Chem 267: 21207–21210

    PubMed  CAS  Google Scholar 

  20. Renz H, Mazer BD, Gelfand EW (1990) Differential inhibition of T- and B-cell function in IL-4-dependent IgE production by cyclosporin A and methylprednisolone. J Immunol 145: 3641–3646

    PubMed  CAS  Google Scholar 

  21. Foxwell BM, Woerly G, Ryffel B (1990) Inhibition of interleukin 4 receptor expression on human lymphoid cells by cyclosporin. Eur J Immunol 20: 1185–1188

    Article  PubMed  CAS  Google Scholar 

  22. Wada K, Kaminuma O, Mori A, Nakata A, Ogawa K, Kikkawa H, Ikezawa K, Suko M, Okudaira H (1998) IL-5-producing T cells that induce airway eosinophilia and hyperresponsiveness are suppressed by dexamethasone and cyclosporin A in mice. Int Arch Allergy Immunol 117 Suppl 1: 24–27

    Article  PubMed  CAS  Google Scholar 

  23. Meng Q, Ying S, Corrigan CJ, Wakelin M, Assoufi B, Moqbel R, Kay AB (1997) Effects of rapamycin, cyclosporin A, and dexamethasone on interleukin 5-induced eosinophil degranulation and prolonged survival. Allergy 52: 1095–1101

    Article  PubMed  CAS  Google Scholar 

  24. Schmidt J, Fleissner S, Heimann Weitschat I, Lindstaedt R, Szelenyi I (1994) The effect of different corticosteroids and cyclosporin A on interleukin-4 and interleukin-5 release from murine TH2- type T cells. Eur J Pharmacol 260: 247–250

    Article  PubMed  CAS  Google Scholar 

  25. Durez P, Abramowitz D, Gerard C, Van Mechelen M, Amraoui Z, Dubois C, Leo O, Velu T, Goldman M (1993) In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 177: 551–555

    Article  PubMed  CAS  Google Scholar 

  26. Zhang JG, Walmsley MW, Moy JV, Cunningham AC, Talbot D, Dark JH, Kirby JA (1998) Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. Transplant Int 11 Suppl 1: S325–S327

    Google Scholar 

  27. Shin GT, Khanna A, Ding R, Sharma VK, Lagman M, Li B, Suthanthiran M (1998) In vivo expression of transforming growth factor-betal in humans: stimulation by cyclosporine. Transplantation 65: 313–318

    Article  PubMed  CAS  Google Scholar 

  28. Wolf G, Zahner G, Ziyadeh FN, Stahl RA (1996) Cyclosporin A induces transcription of transforming growth factor beta in a cultured murine proximal tubular cell line. Exp Nephrol 4: 304–308

    PubMed  CAS  Google Scholar 

  29. Ahuja SS, Shrivastav S, Danielpour D, Balow JE, Boumpas DT (1995) Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes. Transplantation 60: 718–723

    Article  PubMed  CAS  Google Scholar 

  30. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M (1995) Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett 358: 109–112

    Article  PubMed  CAS  Google Scholar 

  31. Khanna A, Li B, Sharma VK, Suthanthiran M (1996) Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-beta expression. Transplant Proc 28: 2015–2018

    PubMed  CAS  Google Scholar 

  32. Shihab FS, Andoh TF, Tanner AM, Noble NA, Border WA, Franceschini N, Bennett WM (1996) Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 49: 1141–1151

    Article  PubMed  CAS  Google Scholar 

  33. Redford TW, Yi AK, Ward CT, Krieg AM (1998) Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol 161: 3930–3935

    PubMed  CAS  Google Scholar 

  34. Chang CC, Aversa G, Punnonen J, Yssel H, de Vries JE (1993) Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro. Ann N Y Acad Sci 696: 108–122

    Article  PubMed  CAS  Google Scholar 

  35. Van Der Pouw K. TC, Boeije LC, Troon JT, Rutschmann SK, Wijdenes J, Aarden LA (1996) Human IL-13 production is negatively influenced by CD3 engagement. Enhancement of IL-13 production by cyclosporin A. J Immunol 156: 1818–1823

    Google Scholar 

  36. Opelz G (1995) Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 60: 1220–1224

    PubMed  CAS  Google Scholar 

  37. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tuckerburden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS et al (1996) Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381: 434–438

    Article  PubMed  CAS  Google Scholar 

  38. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M (1984) Cyclosporine-associated chronic nephropathy. N Engl J Med 311: 699–705

    Article  PubMed  CAS  Google Scholar 

  39. Feutren G, Mihatsch MJ (1992) Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. (International kidney biopsy registry of cyclosporine in autoimmune diseases). N Engl J Med 326: 1654–1660

    Article  PubMed  CAS  Google Scholar 

  40. Bach JF, Feutren G, Noel LH, Hannedouche T, Landais P, Timsit J, Boitard C, Bougneres P, Grunfeld JP, Assan R (1990) Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 22: 1296–1298

    PubMed  CAS  Google Scholar 

  41. Assan R, Timsit J, Feutren G, Bougneres P, Czernichow P, Hannedouche T, Boitard C, Noel LH, Mihatsch MJ, Bach JF (1994) The kidney in cyclosporin A-treated diabetic patients: a long-term clinicopathological study. Clin Nephrol 41: 41–49

    PubMed  CAS  Google Scholar 

  42. Young EW, Ellis CN, Messana JM, Johnson KJ, Leichtman AB, Mihatsch MJ, Hamilton TA, Groisser DS, Fradin MS, Voorhees JJ (1994) A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 46: 1216–1222

    Article  PubMed  CAS  Google Scholar 

  43. Pei Y, Scholey JW, Katz A, Schachter R, Murphy GF, Cattran D (1994) Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Amer J Kidney Dis 23: 528–536

    CAS  Google Scholar 

  44. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, Bourget T, Dimov I, Simpson K, Glass E et al (1996) Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Amer Acad Dermatol 35: 710–719

    Article  CAS  Google Scholar 

  45. Grossman RM, Chevret S, Abi R.J, Blanchet F, Dubertret L (1996) Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 132: 623–629

    Article  PubMed  CAS  Google Scholar 

  46. Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S (1997) Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Brit J Dermatol 136: 531–535

    Article  CAS  Google Scholar 

  47. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L (1998) Renal function after 10 years’ treatment with cyclosporin for psoriasis. Brit J Dermatol 138: 443–449

    Article  CAS  Google Scholar 

  48. Rodriguez F, Krayenbuhl JC, Harrison WB, Forre O, Dijkmans BA, Tugwell P, Miescher PA, Mihatsch MJ (1996) Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum 39: 1491–1498

    Article  PubMed  CAS  Google Scholar 

  49. Sund S, Forre O, Berg KJ, Kvien TK, Hovig T (1994) Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol 41: 33–40

    PubMed  CAS  Google Scholar 

  50. Landewe RB, Dijkmans BA, Van Der Woude FJ, Breedveld FC, Mihatsch MJ, Bruijn JA (1996) Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy. J Rheum 23: 61–64

    PubMed  CAS  Google Scholar 

  51. Zonneveld IM, de Rie MA, Beljaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, Bos JD (1996) The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Brit J Dermatol 135 Suppl 48: 15–20

    Article  CAS  Google Scholar 

  52. Berth-Jones J, Graham Brown RA, Marks R, Camp RD, English JS, Freeman K, Holden CA, Rogers SC, Oliwiecki S, Friedmann PS et al (1997) Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Brit J Dermatol 136: 76–81

    Article  CAS  Google Scholar 

  53. Wang Y, McDuffie M, Nomikos IN, Hao L, Lafferty KJ (1988) Effect of cyclosporine on immunologically mediated diabetes in nonobese diabetic mice. Transplantation 46: 101S–106S

    Article  PubMed  CAS  Google Scholar 

  54. Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Amer J Gastroenterol 88: 646–649

    CAS  Google Scholar 

  55. Actis GC, Ottobrelli A, Pera A, Barletti C, Ponti V, Pinna Pintor M, Verme G (1993) Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 17: 10–13

    Article  PubMed  CAS  Google Scholar 

  56. Feutren G, de The G, Bach JF (1992) Epstein-Barr virus serology and isoelectrofocusing pattern of serum immunoglobulins in cyclosporin or placebo-treated type I diabetics. J Autoimmun 5: 161–172

    Article  PubMed  CAS  Google Scholar 

  57. Cockburn IT, Krupp P (1989) The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 2: 723–731

    Article  PubMed  CAS  Google Scholar 

  58. Arellano F, Krupp P (1993) Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Brit J Rheumatol 32 Suppl 1: 72–75

    Google Scholar 

  59. Collaborative Study Group of Sandimmun in Nephrotic Syndrome (1991) Safety and tolerability of cyclosporin A (Sandimmun) in idiopathic nephrotic syndrome. Clin Nephrol 35 Suppl 1: S48–S60

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U 25, Hôpital Necker, 161 rue de Sèvres, Paris, F-75015, France

    Jean-François Bach

Authors
  1. Jean-François Bach
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Novartis Pharma AG, USA

    Henk-Jan Schuurman

  2. Novartis Pharma AG, Basel, 4002, Switzerland

    Gilles Feutren

  3. Immunologie Clinique, Hôpital Necker, 161 Rue de Sèvres, Paris Cedex 15, France

    Jean-François Bach

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Bach, JF. (2001). Lessons for transplantation of cyclosporine experience in the treatment of autoimmune diseases. In: Schuurman, HJ., Feutren, G., Bach, JF. (eds) Modern Immunosuppressives. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8352-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8352-8_12

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9530-9

  • Online ISBN: 978-3-0348-8352-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation